The death of a UK traveller following a cosmetic procedure in Thailand has exposed an uncomfortable gap in travel insurance: even specialist medical-tourism cover may not respond when the treatment itself causes a catastrophic complication.
An inquest in London last month heard that a 43-year-old man died within hours of undergoing a cosmetic procedure at a clinic in Bangkok. The Times reported that he had travelled to Thailand in early March for a penis enlargement procedure involving a hyaluronic acid filler injection.
Hours later, while having a massage at a Bangkok hotel, he collapsed with severe chest pain and was taken to hospital, where he died. The assistant coroner at Westminster recorded a cause of death of complications from a cosmetic procedure abroad, with post-mortem tests pointing to a pulmonary embolism triggered by the injection.
For the insurance market, the case raises a broader question: what happens when a UK traveller goes abroad specifically for elective treatment and something goes seriously wrong?
According to Vered Lobel, CEO of specialist MGA OneBefore, the starting point is often misunderstood. Standard leisure travel insurance can exclude the entire trip, not simply the treatment itself, when seeking medical treatment is the main reason for travelling.
“All cover is declined if your main purpose for travel is because of a medical reason, you're going to seek treatment abroad,” she said.
The issue is becoming harder to ignore as more people travel overseas for treatment. Office for National Statistics estimates put the number of visits by Great Britain residents for medical treatment at 524,000 in 2024, up from 431,000 in 2023 and 348,000 in 2022.
The figures, drawn from the International Passenger Survey, are estimates rather than a complete count. But they point to substantial growth in a market encompassing cosmetic and dental procedures as well as fertility treatment, bariatric surgery and hip and knee replacements.
“When we looked at it initially, the numbers were about 200,000 to 250,000 [a year] is what we were looking at, but that's grown a lot obviously,” Lobel said.
Dedicated medical-tourism policies have emerged to address the exclusion in conventional travel insurance. OneBefore launched its Globetrotter product in 2024 for people travelling for procedures including hip and knee replacements, cataract treatment, fertility treatment, bariatric surgery, dental work and cosmetic procedures. But specialist cover does not necessarily mean the procedure itself is insured.
Lobel said the policy restores conventional travel protections but does not insure the outcome of the treatment or take on the medical negligence exposure associated with an overseas provider.
“What we're not covering is anything to do with the procedure you're going for. We don't want to be veering into this territory of medical negligence, or the suitability of that surgeon to perform that procedure, because there's no way for us to vet these clinics abroad.”
That distinction becomes particularly significant at the most serious end of a claim. Asked whether a death caused by the procedure, and the subsequent cost of repatriating the body, could fall outside specialist cover, Lobel acknowledged the gap.
“The repatriation of a body is expensive, but the cost is not unlimited. It's very difficult to take responsibility for the actions of doctors that we haven't vetted. So anything to do with an action that those doctors undertake that therefore leads to something like a repatriation, we are not covering. I understand it's a gap, but there's also an element of insurance can't cover everything.”
A policy designed specifically for somebody travelling overseas for treatment can therefore remove the blanket exclusion that would apply under conventional travel insurance without necessarily covering the treatment that prompted the journey.
The risk can become more complicated when travellers combine treatments. Lobel said referrals increasingly involve several procedures being carried out during the same trip, potentially extending the time spent under anaesthetic and increasing the likelihood of life-threatening complications.
The difficulty is that clients may never think to disclose the purpose of the trip. Lobel said people already dealing with a regulated broker are in a stronger position because their insurance needs can be identified and specialist cover found where necessary.
The greater exposure may lie with people relying on bundled travel insurance, including cover attached to bank accounts, who decide to undergo treatment while abroad without realising the purpose of the trip can affect the wider policy.
A traveller planning a holiday alongside dental work, for example, may assume only complications from the treatment are excluded. In reality, Lobel said, they could find an unrelated travel claim declined because seeking treatment was the main purpose of the journey.
Clients travelling specifically for cosmetic surgery, dental work or other elective procedures may need specialist cover to restore protections they assume they already have. But buying that policy does not necessarily transfer the central risk of the trip: that the treatment itself goes wrong.
As outbound medical tourism grows, that distinction becomes harder to treat as a niche concern. The gap is not just whether travellers have insurance, but whether they understand that even a policy bought specifically for treatment abroad can leave the treatment itself outside the cover.
